Flu
32
2
3
22
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
9.4%
3 terminated out of 32 trials
88.0%
+1.5% vs benchmark
28%
9 trials in Phase 3/4
23%
5 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (32)
Behavioral Economics to Improve Flu Vaccination Using EHR Nudges Replication
Improved Immunology Outcomes Associated With Lactoferrin Fortified With HMO in Infant Formula
Quantification of Viral Load in the Upper Respiratory Tract in Patients Treated With Olsetamivir for Influenza
Preparedness Through Respiratory Virus Epidemiology and Community Engagement
Burden of Influenza at Emergency Department Level : BIED
Can the Ergometric Test in Flu-like Syndrome Help in the Outcome Analysis of Unvaccinated Patients
Behavioral Economics to Improve Flu Vaccination Using EHR Nudges
FLUAD vs. FLUZONE HD Influenza Vaccine in Residents of Long Term Care
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.
Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine
Elderberry for Immune Support
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines
Ability of Beta-glucan Supplementation to Augment Immune Function
PET-CT Scans in Healthy Volunteers After Flu Vaccination
Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers
A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects